INTEGRATIVE RADIOMICS MODELS TO PREDICT BIOPSY RESULTS FOR NEGATIVE PROSTATE MRI.
Computer-aided diagnosis
MRI
prostate cancer
radiomics
Journal
Proceedings. IEEE International Symposium on Biomedical Imaging
ISSN: 1945-7928
Titre abrégé: Proc IEEE Int Symp Biomed Imaging
Pays: United States
ID NLM: 101492570
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
entrez:
27
1
2022
pubmed:
28
1
2022
medline:
28
1
2022
Statut:
ppublish
Résumé
Multi-parametric MRI (mpMRI) is a powerful non-invasive tool for diagnosing prostate cancer (PCa) and is widely recommended to be performed before prostate biopsies. Prostate Imaging Reporting and Data System version (PI-RADS) is used to interpret mpMRI. However, when the pre-biopsy mpMRI is negative, PI-RADS 1 or 2, there exists no consensus on which patients should undergo prostate biopsies. Recently, radiomics has shown great abilities in quantitative imaging analysis with outstanding performance on computer-aid diagnosis tasks. We proposed an integrative radiomics-based approach to predict the prostate biopsy results when pre-biopsy mpMRI is negative. Specifically, the proposed approach combined radiomics features and clinical features with machine learning to stratify positive and negative biopsy groups among negative mpMRI patients. We retrospectively reviewed all clinical prostate MRIs and identified 330 negative mpMRI scans, followed by biopsy results. Our proposed model was trained and validated with 10-fold cross-validation and reached the negative predicted value (NPV) of 0.99, the sensitivity of 0.88, and the specificity of 0.63 in receiver operating characteristic (ROC) analysis. Compared with results from existing methods, ours achieved 11.2% higher NPV and 87.2% higher sensitivity with a cost of 23.2% less specificity.
Identifiants
pubmed: 35082974
doi: 10.1109/isbi48211.2021.9433879
pmc: PMC8786598
mid: NIHMS1771994
doi:
Types de publication
Journal Article
Langues
eng
Pagination
877-881Subventions
Organisme : NCI NIH HHS
ID : R01 CA248506
Pays : United States
Références
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Biom J. 2008 Jun;50(3):419-30
pubmed: 18435502
J Urol. 2020 Jul;204(1):24-32
pubmed: 31967522
J Urol. 2017 Sep;198(3):575-582
pubmed: 28373135
J Urol. 2019 Feb;201(2):268-276
pubmed: 30189186
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
Sci Rep. 2019 Feb 7;9(1):1570
pubmed: 30733585
J Magn Reson Imaging. 2018 Feb 22;:
pubmed: 29469937
Eur Urol. 2018 Jul;74(1):48-54
pubmed: 29566957
Nephron Clin Pract. 2010;115(2):c94-9
pubmed: 20407272
BJU Int. 2018 Jul;122(1):13-25
pubmed: 29699001
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
Biomed Res Int. 2014;2014:789561
pubmed: 25525604
J Urol. 2019 Sep;202(3):498-505
pubmed: 30958743